Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Her2+
•
HR+
What adjuvant chemotherapy would you recommend for a postmenopausal woman with history of porphyria and newly diagnosed T2 N0 triple positive breast cancer?
Related Questions
In a patient with ER+/HER2+ breast cancer with significant residual disease post neoadjuvant TCHP, is there a role of using CDK4/6i in the adjuvant setting with T-DM1?
Would you give adjuvant endocrine therapy to a premenopausal woman with early stage node positive breast cancer that was ER negative, PR positive (60%) and HER2 positive?
How long would you continue trastuzumab and pertuzumab in a patient with ER+ HER2+ breast cancer with initially osseous involvement treated with ACT-HP and is now in CR by PET for >2 years?
Would you treat a patient with cT2 ER+/HER2+ breast cancer with neoadjuvant HER2 directed therapy if HER2 positivity is group 3?
What is your preferred first line therapy for metastatic HR+ inflammatory breast cancer?
How do you manage steroid refractory pneumonitis due to docetaxel or trastuzumab?
How would you approach adjuvant systemic therapy in a HR+ premenopausal patient over the age of 50?
How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?
How do you interpret the EBCTCG meta-analysis analyzing the magnitude of benefit of anthracyclines in early stage ER+ breast cancer?
For Her2+ Stage I T1cN0 patients where neoadjuvant therapy is desired to select out patients for post-operative TDM1, is it reasonable to de-escalate neoadjuvant therapy to THP as opposed to TCHP?
